No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Samsung Bioepis Commences Phase 3 Trials for Keytruda® Biosimilar
On 5 April 2024, Samsung Bioepis announced the commencement of Phase 3 clinical trials for SB27, biosimilar to MSD’s Keytruda® (pembrolizumab) in patients with metastatic non-squamous non-small cell lung cancer (NCT06348199). Biocad initiated phase 1 clinical trials...